More Antimicrobial Peptides Didn't Prevent Skin Parasite Infection — Highlighting AMP Limitations | Research

The takeaway

Mice susceptible to Leishmania skin infection produced more antimicrobial peptides than resistant mice but still got sicker, showing that AMPs alone cannot overcome parasitic infections.

All 6 AMPs upregulated
Despite expressing more antimicrobial peptides than resistant mice, susceptible BALB/c mice still developed cutaneous leishmaniasis — proving AMPs alone are insufficient

What the researchers found

Paradoxically, BALB/c mice (the Leishmania-susceptible strain) showed significantly higher expression of all tested antimicrobial peptide genes (mBD-1, mBD-2, mBD-3, mBD-4, mBD-6, and CRAMP) compared to C57BL/6 mice (the resistant strain). Despite this higher AMP expression, BALB/c mice still developed cutaneous leishmaniasis.

The cytokine profiles confirmed expected immune responses: susceptible BALB/c mice had elevated IL-10 (anti-inflammatory) and reduced IL-12, while resistant C57BL/6 mice showed the opposite pattern. This demonstrates that elevated antimicrobial peptide expression alone cannot overcome Leishmania infection when the broader immune response is skewed toward susceptibility.

Why it matters

Antimicrobial peptides like defensins and cathelicidins are often assumed to provide direct protection against pathogens. This study challenges that assumption for parasitic infections: the most susceptible mice actually produced more AMPs, yet still got sicker. This reveals important limitations of antimicrobial peptides against intracellular parasites like Leishmania and underscores that peptide-based innate immunity is necessary but not sufficient without proper adaptive immune support.

The numbers in context

6 AMP genes tested (mBD-1, -2, -3, -4, -6, CRAMP) · All upregulated in susceptible BALB/c · 2 mouse strains compared · 3 time points (1, 3, 7 days PI) · 5×10⁶ parasites/ml inoculum

How the study worked

BALB/c (susceptible) and C57BL/6 (resistant) mice were subcutaneously infected with L. major promastigotes (5×10⁶/ml). Skin samples were collected at 1, 3, and 7 days post-infection. mRNA levels of six antimicrobial peptide genes (mBD-1 through mBD-6 and CRAMP), IL-10, IL-12, and parasite load were measured using standard molecular methods.

Who was studied

BALB/c and C57BL/6 mice experimentally infected with Leishmania major

What this study cannot tell us

The study measured mRNA expression but not protein levels or antimicrobial activity of the peptides in the skin. The early time points (1-7 days) may not capture the full immune response timeline. The study does not determine whether the elevated AMP expression in susceptible mice is a cause, consequence, or compensatory response to higher parasite burden. Only one Leishmania strain was tested.

How to read the evidence

This is a preclinical mouse infection study measuring gene expression at multiple time points. The two-strain comparison is a standard and well-validated approach for studying Leishmania immunity, but the findings are limited to the murine model.

When this study was published

Published in 2018, this study addresses an understudied area — the role of antimicrobial peptides in parasitic infections. The findings remain relevant as AMPs continue to be explored as therapeutics.

The bigger picture

As antimicrobial peptides are developed as therapeutics, understanding their limitations is as important as understanding their strengths. This study demonstrates that for intracellular parasites like Leishmania, which hide inside immune cells, extracellular AMPs may not reach their target. It suggests that AMP-based therapies for parasitic diseases would need to be combined with immune-modulating approaches to be effective.

Questions still open

Are the elevated AMPs in susceptible mice a compensatory response to higher parasite burden rather than a proactive defense?
Could antimicrobial peptides be effective against Leishmania if combined with immune-modulating therapies that correct the Th1/Th2 balance?
Do cathelicidins and defensins have any direct anti-Leishmania activity in vitro, even if they fail in the susceptible host context?

Common questions

If antimicrobial peptides fight infections, why didn't more peptides mean better protection?

Antimicrobial peptides work well against bacteria and fungi that are exposed to them outside of cells. But Leishmania parasites hide inside immune cells (macrophages), where skin-produced AMPs can't reach them. The susceptible mice produced more AMPs as a reaction to higher parasite burden, but the peptides couldn't access the parasites in their intracellular hideout. Meanwhile, the broader immune response — controlled by cytokines like IL-10 and IL-12 — determined whether the infection was cleared or progressed.

What is cutaneous leishmaniasis?

Cutaneous leishmaniasis is a parasitic skin disease caused by Leishmania parasites transmitted through sandfly bites. It causes skin sores and ulcers that can be disfiguring and difficult to treat. It affects millions of people in tropical and subtropical regions. Current treatments are limited, toxic, and increasingly face drug resistance — making new approaches including peptide-based therapies an active area of research.

Read the original research

Host-parasite Responses Outcome Regulate the Expression of Antimicrobial Peptide Genes in the Skin of BALB/c and C57BL/6 Murine Strains Following Leishmania major MRHO/IR/75/ER Infection.

Iranian journal of parasitology, 13(4), 515-523

View on PubMed ↗

Citation

Daneshvar, Hamid; Tavakoli Kareshk, Amir; Sharifi, Iraj; Keyhani, Alireza; Tavakoli Oliaee, Razieh; Asadi, Arash. (2018). Host-parasite Responses Outcome Regulate the Expression of Antimicrobial Peptide Genes in the Skin of BALB/c and C57BL/6 Murine Strains Following Leishmania major MRHO/IR/75/ER Infection.. Iranian journal of parasitology, 13(4), 515-523.